Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
Hepatic encephalopathy (HE) is a serious complication of acute and chronic liver disease associated with severe morbidity and mortality. We performed updated random effects meta-analyses to evaluate the evidence for non-absorbable disaccharides (lactulose and lactitol), rifaximin and branched chain amino acids (BCAA). A meta-analysis of randomized trials showed that, compared with placebo or no intervention, non-absorbable disaccharides have beneficial effects on HE manifestations and prevention of HE episodes. The addition of rifaximin to non-absorbable disaccharides versus rifaximin alone was more beneficial than non-absorbable disaccharides used alone on both outcome measures. Likewise, a meta-analysis of randomised controlled trials found that oral BCAA supplements have beneficial effects on manifestations of HE compared with control supplements. The effect was found in a variety of clinical settings. No convincing effects of intravenous BCAA for episodic HE were identified. In conclusion, evidence-based treatment recommendations for patients with HE should include non-absorbable disaccharides combined with rifaximin or BCAA. Additional evidence is needed to evaluate the effect of combining all three interventions.
KeywordsCirrhosis Meta-analysis Systematic Review Randomized controlled trials
- Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C (2003) Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev (2): CD001939Google Scholar
- Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140(2):478-487 e471Google Scholar
- Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, Stravitz RT, Luketic V, Fuchs M, White MB, Bell DE, Gilles H, Morton K, Noble N, Puri P, Sanyal AJ (2011b) The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol 106(9):1646–1653PubMedCrossRefGoogle Scholar
- Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35(3):716–721PubMedCrossRefGoogle Scholar
- Germain L, Frexinos J, Louis A, Ribet A (1973) Double blind study of lactulose in 18 patients with chronic hepatic encephalopathy after portocaval shunt. Archives Francaises des Maladies de L'appareil Digestif 62(4):293–302Google Scholar
- Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, Flavia M, Jacas C, Minguez B, Vergara M, Soriano G, Vila C, Esteban R, Cordoba J (2011) Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol 106(6):1081–1088PubMedCrossRefGoogle Scholar
- Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45(3):549–559Google Scholar
- Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther 34(8):853–861PubMedCrossRefGoogle Scholar
- Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, Als-Nielsen B, Balk EM, Gluud C, Gluud LL, Ioannidis JP, Schulz KF, Beynon R, Welton NJ, Wood L, Moher D, Deeks JJ, Sterne JA (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157(6):429–438Google Scholar